Newswire

CDER Launches Quantitative Medicine Center of Excellence to Enhance Drug Development

The Center for Drug Evaluation and Research (CDER) has established a new Quantitative Medicine Center of Excellence (QM CoE) aimed at advancing the integration of quantitative methodologies in drug development and regulatory decision-making. This initiative is designed to ensure a consistent and evolving application of quantitative medicine principles across CDER’s operations.

The QM CoE will serve as a pivotal resource for regulatory professionals, offering guidance and support in the application of quantitative approaches that can enhance the efficiency and effectiveness of drug evaluation processes. By fostering collaboration among various stakeholders, the center aims to streamline the integration of quantitative data into regulatory frameworks, ultimately improving the quality of submissions and outcomes.

This development signifies a strategic shift towards more data-driven decision-making in the pharmaceutical industry, which may lead to faster approvals and improved patient outcomes. As the industry adapts to these changes, professionals in regulatory, QA/QC, CMC, and sourcing roles will need to align their practices with the evolving standards set forth by the QM CoE.

Explore deeper: the API & FDF Intelligence database is more than a directory. It combines global coverage of APIs, excipients, and finished dosage forms with real market intelligence. You’ll find: – Price ranges for APIs, excipients, and formulations. – DMF, CEP, and GMP compliance status. – Manufacturer portfolios by product and geography. – Direct contacts for every producer and FDF holder, ready for outreach. Instead of scattered spreadsheets and endless searches, the entire picture is a few clicks away. Subscription starts at an accessible rate — see how much time and budget you save by centralizing everything.
Start your 7-day trial and see what the database can do →